1,3-Dimethylol-5,5-dimethylhydantoin

1,3-Dimethylol-5,5-dimethylhydantoin



Associated High Confidence AOPs
For more information or term definitions, please refer to HELP page.

Associated AOPs with Level of Relevance 1
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:15Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutationsGenetic DiseaseWPHA/WNT Endorsed0.25KE:185Increase, Mutations
AOP:139Alkylation of DNA leading to cancer 1Cancer-0.25KE:185Increase, Mutations
AOP:272Deposition of energy leading to lung cancerCancerWPHA/WNT Endorsed0.29KE:1636Increase, Chromosomal aberrations
KE:185Increase, Mutations
AOP:303Frustrated phagocytosis-induced lung cancerCancerUnder Development0.14KE:1669Increased, DNA damage and mutation
AOP:409Frustrated phagocytosis leads to malignant mesotheliomaCancer-0.12KE:1669Increased, DNA damage and mutation
AOP:416Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathwayCancer-0.17KE:1669Increased, DNA damage and mutation
AOP:417Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathwayCancer-0.2KE:1669Increased, DNA damage and mutation
AOP:451Interaction with lung resident cell membrane components leads to lung cancerCancer-0.11KE:1669Increased, DNA damage and mutation
AOP:478Deposition of energy leading to occurrence of cataractsNervous System Disease; Monogenic DiseaseUnder Review0.2KE:1636Increase, Chromosomal aberrations
KE:185Increase, Mutations
AOP:534Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stressCancer-0.17KE:1553Increase mutations

Associated AOPs with Level of Relevance 2
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:293Increased DNA damage leading to increased risk of breast cancerGenetic Disease; Thoracic Disease; CancerUnder Development0.11KE:185Increase, Mutations
AOP:294Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancerGenetic Disease; Thoracic Disease; CancerUnder Development0.11KE:185Increase, Mutations
AOP:296Oxidative DNA damage leading to chromosomal aberrations and mutationsGenetic Disease; Chromosomal DiseaseWPHA/WNT Endorsed0.4KE:185Increase, Mutations
KE:1636Increase, Chromosomal aberrations
AOP:397Bulky DNA adducts leading to mutationsGenetic DiseaseUnder Development0.33KE:185Increase, Mutations

Associated AOPs with Level of Relevance 3
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:232NFE2/Nrf2 repression to steatosisGastrointestinal System Disease; Inherited Metabolic Disorder-0.12KE:1417NFE2/Nrf2 repression
AOP:443DNA damage and mutations leading to Metastatic Breast CancerThoracic Disease; CancerUnder Development0.3KE:1669Increased, DNA damage and mutation
KE:1554Increase Chromosomal Aberrations
KE:185Increase, Mutations
AOP:507Nrf2 inhibition leading to vascular disrupting effects via inflammation pathwayCardiovascular System Disease-0.17KE:1417NFE2/Nrf2 repression
AOP:508Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathwayCardiovascular System Disease-0.14KE:1417NFE2/Nrf2 repression
AOP:509Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunctionCardiovascular System Disease-0.14KE:1417NFE2/Nrf2 repression

No associated AOPs with Level of Relevance 5
DISCLAIMER

TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.